Developed by Eli Lilly, this synthetic peptide consists of 39 amino acids and is engineered with a C20 fatty diacid modification, which extends its half-life and enables convenient once-weekly subcutaneous dosing
Notably, no discernible heterogeneity was observed among the studies ( I 2 = 0%, p = 0.75), prompting the utilization of a fixed-effect model for result reporting
27 A timeline of different trials regarding GLP-1 RAs is presented in Figure 1
These treatments are generally effective in managing the infection, though some patients may require longer courses or repeated treatments
Kaufman reported that after embracing doctors and patients reports and launching the trial, RECOVER is not following ME/CFS and long-COVID doctors experience when it comes to running the trial
Many patients prefer tablets over injections, which has created an opening for misleading marketing